JAAD article raises refill ethics in asynchronous teledermatology

The Journal of the American Academy of Dermatology lists “Refills without follow-up: Ethical duties in asynchronous teledermatology” for November 2026, Volume 95, Issue 5. The record names six authors but supplies no abstract.

Anshu Jonnalagadda, Weston P. Lowry, Joyce Quon, Amar D. Desai, Albert E. Zhou and Jane M. Grant-Kels authored the paper. Its title addresses ethical duties surrounding refills without follow-up in asynchronous teledermatology; no study design, patient cohort or findings appear in the citation.

What does the article address?

Jonnalagadda and colleagues titled the paper “Refills without follow-up: Ethical duties in asynchronous teledermatology.” That wording establishes the topic, not the clinical verdict.

The title joins a care action—refill—to an absence—follow-up—and sets both within asynchronous teledermatology. It does not say whether the authors consider that sequence acceptable under some conditions, unacceptable under others or a problem only when specified clinical thresholds are unmet.

Because the citation supplies no supporting text, the headline cannot establish a position on acceptable refill practice. It also does not define “follow-up” as no contact, delayed contact or contact through another channel; the title leaves each possibility unresolved.

What evidence does the citation provide?

The available citation leaves the evidence base unspecified. Readers cannot determine whether the article reports data, argues a position or combines both.

• Article type: The citation does not label the paper as original research, a review, a commentary or another format.
• Cohort: It gives no patient number, age range, sex, geography, insurance status or teledermatology setting.
• Condition: It names no dermatologic diagnosis, lesion characteristic, severity measure or disease stage.
• Clinical intervention: It identifies no medication, concentration, dose, refill interval or treatment protocol.
• Follow-up: It provides no contact schedule, follow-up duration or definition of follow-up.
• Outcomes: It reports no clinical, safety, adherence or satisfaction outcome.
• Recommendations: It states no refill standard, escalation criterion, exception or required documentation.
• Jurisdiction: It gives no country, state, payer policy, legal authority or regulatory requirement.

That gap prevents a defensible conclusion about frequency, causality or safety. A title can frame an ethical problem without showing how often it occurs, what follows it or how clinicians respond.

Does the citation establish a new standard?

Nothing in the November 2026 citation establishes that JAAD changed a clinical standard or issued new policy. It names no threshold for a refill, no required follow-up interval and no exception process.

The record also does not assign the duty to one party. It does not state whether recommendations address clinicians, health systems, telemedicine services or patients, and it gives no legal or regulatory analysis by jurisdiction.

Without the full text, describing the authors as supporting or opposing routine refills would go beyond the record. No conclusion about quality of care can follow from bibliographic metadata alone.

The citation contains no quotation from any of the six authors beyond the title. It therefore supports no attributed statement about when follow-up is necessary or unnecessary.

What can readers report now?

Three facts can be reported without qualification:

• November 2026: The article appears in JAAD Volume 95, Issue 5.
• Six authors: The list runs from Anshu Jonnalagadda to Jane M. Grant-Kels.
• Named subject: The title links refills without follow-up to ethical duties in asynchronous teledermatology.

That is the full evidentiary boundary of the available record. Any summary that adds a drug, disease, patient count, follow-up duration, outcome or author position would invent detail. The next useful update will come from the full text, particularly its article type, methods and exact recommendations.